Lung Cancer Circle of Hope

03/06/2026

https://www.uchicagomedicine.org/forefront/cancer-articles/drug-infusion-lights-up-small-lung-cancer-tumors

Lung cancer patient Jane Jud became the first person at UChicago Medicine to use Cytalux, an illuminating agent that helps surgeons find small and hard-to-locate cancer tissue.

03/05/2026

https://www.moffitt.org/newsroom/news-releases/moffitt-study-identifies-distinct-tumor-immune-ecologies-that-predict-immunotherapy-response-in-lung-cancer/

Study shows tumor microenvironment ecology predicts response better than PD-L1 status alone

03/04/2026

https://www.drugtargetreview.com/news/193742/blocking-growth-hormone-may-improve-resistant-lung-cancer-treatment/

Explore new strategies for treating resistant lung cancer. Discover how blocking growth hormone receptors may improve outcomes.

03/03/2026

https://medicine.yale.edu/news-article/gaps-in-lung-cancer-treatment-persist-yale-study-finds/

In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically improved outcomes. But according to new

02/28/2026

https://www.ohio.edu/news/2026/02/new-study-identifies-growth-hormone-receptor-possible-target-improve-lung-cancer

Ohio University researchers have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

02/26/2026

On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.

02/26/2026

https://www.managedhealthcareexecutive.com/view/mayo-clinic-research-shows-why-lung-cancer-resists-immunotherapy

Blocking the protein P2RX7 in regulatory T cells boosted antibody responses, and this discovery could one day lead to strategies for enhancing existing immunotherapies in non-small lung cancer.

02/25/2026

https://www.hadassah.org/press-release/hadassah-study-shows-safety-and-early-efficacy-of-p-cures-upright-proton-therapy-for-lung-cancer

Released Feb 24, 2026. Hadassah study shows viability of P-Cure’s Upright Proton Therapy for lung cancer.

02/24/2026

https://www.wbay.com/2026/02/23/most-americans-eligible-lung-cancer-screening-arent-getting-tested-study-finds/

A study found fewer than 1 in 5 current or former smokers over 50 are getting the quick screening.

02/23/2026

https://www.ndtv.com/health/lung-cancer-symptoms-6-unusual-signs-of-the-deadly-disease-you-should-know-11121136

Lung cancer was the most commonly occurring cancer worldwide in 2022. It accounted for 2.5 million new cases which is 12.4% of the total new cases.

02/22/2026

https://www.uclahealth.org/news/article/ucla-doctors-perform-rare-robotic-heart-lung-surgery-2

Breadcrumb Home News & Insights UCLA doctors perform rare robotic heart-lung surgery Multidisciplinary team treats two complex conditions in one combined operation. Dr. Arjan Gower, left, Dr. Richard J. Shemin and Dr. Bryan M. Burt collaborated on complex cardiovascular and oncological care. Februar...

02/20/2026

https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-study-identifies-mechanism-behind-immunotherapy-resistance-in-lung-cancer/

Mayo Clinic researchers identify how P2RX7-driven regulatory T cells promote immunotherapy resistance in lung cancer, pointing to a potential new treatment strategy.